

Exhibit I

**Deposition of Terri-Lee Nataline
December 14, 2009**

Terri-Lee Nataline, Esquire
Confidential – Subject to Further Confidentiality Review

1

UNITED STATES DISTRICT COURT
FOR THE SOUTHERN DISTRICT OF WEST VIRGINIA
CHARLESTON DIVISION

- - -

IN RE: DIGITEK® PRODUCTS : MDL NO.
LIABILITY LITIGATION : 1968

(This document relates to all cases.)

- - -

CONFIDENTIAL - SUBJECT TO FURTHER
CONFIDENTIALITY REVIEW

- - -

New York, New York
Monday, December 14, 2009

- - -

Videotaped Deposition of TERRI-LEE
NATALINE, ESQUIRE, held at Harris Beach PLLC,
100 Wall Street, 24th Floor, on the above
date, beginning at 9:34 a.m., before Kimberly
A. Otherwise, a Certified Realtime Reporter
and Notary Public.

- - -

GOLKOW TECHNOLOGIES, INC.
877.370.3377 ph | 917.591.5672 fax
deps@golkow.com

GOLKOW TECHNOLOGIES, INC. - 1.877.370.3377

Terri-Lee Nataline, Esquire
Confidential – Subject to Further Confidentiality Review

45

1 manufacturing practices regulations that the
2 FDA puts out, are they applicable to all the
3 drugs that Actavis manufactures?

4 A Yes.

5 Q Are there any differences between
6 the standards applicable to Digitek and those
7 GMP standards applicable to the other drugs
8 made by the company?

9 A No.

10 Q What's the purpose of GMPs?

11 MR. ANDERTON: Objection.

12 You may answer.

13 THE WITNESS: It's to ensure
14 good manufacturing procedures. It's to
15 make sure that, you know, the proper
16 procedures are followed and the product
17 is made in the appropriate manner.

18 BY MR. BLIZZARD:

19 Q Okay. Does it relate to safety?

20 MR. ANDERTON: Objection.

21 You may answer.

22 THE WITNESS: It depends -- it
23 depends on -- potentially, yes.

24